. 2020 Dec 16;41(4):671–678. doi: 10.1097/IAE.0000000000003083

Table 3.

Incidence of RPE Tear Across Retrospective Case Series With Anti-VEGF Treatment

Study	Treatment	Duration, Months	Eyes, n	Incidence of RPE Tear Across Treatment Groups, n (%)	Incidence of PED Across Treatment Groups, n (%)	Incidence of RPE Tear in Patients With PED, n (%)
Chan et al¹¹	Bevacizumab^*	12	1,064	22 (2.2)	123 (11.6)	21 (17.1)
Gelisken et al³⁰	Bevacizumab^*	12	409	15 (3.7)	NS	NS^†
Leitritz et al³¹	Bevacizumab^*	NA	393	15 (3.8)	NS	14.8
Empeslidis et al¹²	Ranibizumab or bevacizumab^*	18	628^‡	17 (2.7)	NS	NS
Konstantinidis et al³²	Ranibizumab	24	74	4 (5.4)	NA	7 (12.3)

Bevacizumab is not licensed for the treatment of retinal diseases.

^†

Patients with serious PED were excluded.

^‡

Number of patients.

NA, not applicable; NS, not stated.